Tannock IF - Search Results

1

Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.

Mayers C, Panzarella T, Tannock IF. Mayers C, et al. Among authors: tannock if. Cancer. 2001 Jun 15;91(12):2246-57. Cancer. 2001. PMID: 11413512

2

Comparison of Eligibility Criteria Between Protocols, Registries, and Publications of Cancer Clinical Trials.

Zhang S, Liang F, Li W, Tannock I. Zhang S, et al. J Natl Cancer Inst. 2016 May 25;108(11). doi: 10.1093/jnci/djw129. Print 2016 Nov. J Natl Cancer Inst. 2016. PMID: 27226519

3

Requirement of the Na+/H+ exchanger for tumor growth.

Rotin D, Steele-Norwood D, Grinstein S, Tannock I. Rotin D, et al. Cancer Res. 1989 Jan 1;49(1):205-11. Cancer Res. 1989. PMID: 2535690

4

Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours.

Newell K, Wood P, Stratford I, Tannock I. Newell K, et al. Br J Cancer. 1992 Aug;66(2):311-7. doi: 10.1038/bjc.1992.262. Br J Cancer. 1992. PMID: 1503904 Free PMC article.

5

Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience.

Choo R, Tannock I. Choo R, et al. Cancer. 1991 Nov 15;68(10):2120-4. doi: 10.1002/1097-0142(19911115)68:10<2120::aid-cncr2820681005>3.0.co;2-7. Cancer. 1991. PMID: 1913449

6

Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak AR. Manji A, et al. Among authors: tannock if. J Clin Oncol. 2013 Nov 20;31(33):4260-7. doi: 10.1200/JCO.2012.47.4957. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127441 Review.

7

Evaluation of treatment benefit: randomized controlled trials and population-based observational research.

Booth CM, Tannock IF. Booth CM, et al. Among authors: tannock if. J Clin Oncol. 2013 Sep 10;31(26):3298-9. doi: 10.1200/JCO.2013.51.5023. Epub 2013 Aug 12. J Clin Oncol. 2013. PMID: 23940222 No abstract available.

8

Evolution of the randomized controlled trial in oncology over three decades.

Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Booth CM, et al. Among authors: tannock if. J Clin Oncol. 2008 Nov 20;26(33):5458-64. doi: 10.1200/JCO.2008.16.5456. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955452 Free PMC article.

9

Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.

Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF. Bedard PL, et al. Among authors: tannock if. J Clin Oncol. 2007 Aug 10;25(23):3482-7. doi: 10.1200/JCO.2007.11.3670. J Clin Oncol. 2007. PMID: 17687153

10

Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.

Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF. Niraula S, et al. Among authors: tannock if. J Clin Oncol. 2014 Nov 10;32(32):3634-42. doi: 10.1200/JCO.2014.55.8437. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267757

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results